Cardamom for Blood Pressure and Heart Health

Search for cardamom and blood pressure and you will find dozens of confident pages. Nearly all of them trace back to a single study of twenty people, with no control group, published in 2009. That is not a scandal — it is a perfectly respectable pilot study, honestly reported by its authors, and it found something worth following up. What is a problem is the fifteen years of copy that turned it into "cardamom lowers blood pressure" without ever mentioning that everyone in it received cardamom and nobody received a placebo.

This page walks through that study in full, explains exactly why an uncontrolled trial in newly diagnosed hypertension is the study design most likely to produce a false positive, sets out the animal pharmacology that makes the hypothesis reasonable in the first place, and covers one finding from the same paper that deserves far more attention than the blood-pressure result: increased fibrinolytic activity, which matters if you take an anticoagulant.

Everything here concerns green cardamom, Elettaria cardamomum, at the dose used in human research: 3 grams a day of powder. Black cardamom (Amomum subulatum) is a different genus with its own separate and thinner literature, and its studies do not transfer.

Table of Contents

1. The Claim and Its Single Source
2. Inside the 2009 Rajasthan Study
3. Why Twenty People and No Control Group Cannot Settle This
4. The Animal and Isolated-Tissue Mechanisms
5. Fibrinolysis and the Bleeding Question
6. Antioxidant Status and Endothelial Function
7. Diuretic and Sedative Effects
8. What the Meta-Analysis Found About Lipids
9. Salt, Potassium and the Much Bigger Lever
10. Using Cardamom Alongside Blood-Pressure Medication
11. The Defensible Bottom Line
12. Key Research Papers
13. Connections

The Claim and Its Single Source

The claim as it usually appears is that cardamom lowers blood pressure, sometimes with a specific figure attached. The source, in essentially every case, is:

Verma SK, Jain V, Katewa SS. Blood pressure lowering, fibrinolysis enhancing and antioxidant activities of cardamom (Elettaria cardamomum), Indian Journal of Biochemistry and Biophysics, 2009.

It is worth being precise about what that paper is and is not. It is a real study, conducted in Rajasthan, India, published in a peer-reviewed journal, and reported with commendable transparency about its own design — the authors do not oversell it. It is also a single-arm, uncontrolled, unblinded pilot study in twenty participants, which in the hierarchy of clinical evidence sits several rungs below the randomized controlled trial that the claim requires.

What makes this particularly worth flagging is that green cardamom does have properly designed placebo-controlled trials — they exist, they are discussed on the companion metabolic and antioxidant page, and they were conducted in adults with fatty liver disease and type 2 diabetes on metabolic endpoints. The population where cardamom's most popular cardiovascular claim originates is the one population where nobody ran a controlled trial.

Inside the 2009 Rajasthan Study

Evidence tier: uncontrolled human pilot study.

The design, as reported:

• Participants: twenty adults with newly diagnosed primary (stage 1) hypertension. Not established, treated hypertension — newly diagnosed, and not yet on medication.
• Intervention: 3 grams of cardamom powder per day, given in two divided doses.
• Duration: 12 weeks.
• Comparison: none. There was no placebo group, no untreated control group, and no blinding. Every participant received cardamom, and outcomes were compared with the same participants' own baseline values.

The reported results, at twelve weeks:

• Systolic, diastolic and mean arterial blood pressure all fell significantly from baseline (reported at p<0.001).
• Fibrinolytic activity rose significantly — the body's clot-dissolving capacity increased.
• Total antioxidant status increased by approximately 90 percent.
• Blood lipids and fibrinogen did not change.
• Participants reported a general sense of wellbeing, and no side effects were recorded.

Read on its own terms, that is a clean, internally consistent pilot result and a sensible reason to fund a larger trial. The safety observation — three grams a day for three months with no adverse effects — is genuinely useful information and holds up independently of the efficacy question.

Why Twenty People and No Control Group Cannot Settle This

The absence of a control group is not a technicality. In hypertension research specifically, it is close to fatal, and there are four separate reasons stacked on top of each other.

1. Regression to the mean

This is the big one. Blood pressure is not a fixed property of a person; it varies substantially from hour to hour and day to day. People are diagnosed with hypertension when a measurement comes in high — which means the cohort has been selected, by construction, at a moment when their fluctuating value was toward the top of its range. Measure the same people again weeks later and the average will drift downward, toward each person's true mean, with no treatment at all. The steeper the selection, the larger this artefact, and "newly diagnosed on the basis of an elevated reading" is a steep selection.

2. The white-coat effect and habituation

A first blood-pressure measurement in a clinical setting is systematically higher than later ones in the same person. Familiarity with the room, the cuff, the observer and the procedure reduces the reading over subsequent visits. Twelve weeks of repeated measurement produces a downward trend purely from habituation.

3. The trial effect

Enrolling in a study changes behaviour. Participants who have just been told they have high blood pressure and are now being monitored every few weeks tend to eat differently, drink less alcohol, take more exercise, sleep more and attend to their salt intake — all of which lower blood pressure, and none of which are the intervention. A placebo group experiences all of that too, which is precisely why it is there.

4. Sample size and blinding

Twenty people is a very small sample for an outcome as variable as blood pressure. And because nobody was blinded, both the participants and whoever measured them knew that cardamom was being taken — and blood-pressure measurement, unless fully automated, is susceptible to observer expectation.

Put together: a single-arm study of twenty newly diagnosed hypertensive people measured repeatedly over twelve weeks would be expected to show a significant fall in blood pressure whether the intervention did anything at all. That is not a criticism of the authors, who designed a pilot and reported it as one. It is a reason the result cannot be quoted as a finding about cardamom.

And the follow-up has not happened. In the years since, no adequately powered, placebo-controlled trial of cardamom for hypertension has been published. The controlled trials that do exist went after lipids and glucose. Blood pressure — cardamom's most-searched cardiovascular claim — remains untested under controlled conditions.

The Animal and Isolated-Tissue Mechanisms

Evidence tier: preliminary — isolated tissue and rodent work.

The hypothesis is not arbitrary. Gilani, Jabeen, Khan and Shah, Gut modulatory, blood pressure lowering, diuretic and sedative activities of cardamom, Journal of Ethnopharmacology, 2008, reported several relevant findings from a single programme of animal work: blood-pressure lowering in anaesthetised rats, a diuretic effect, sedative activity in behavioural testing, and gut effects consistent with calcium-channel blockade at higher concentrations.

Calcium-channel blockade is the interesting part, because it is a real and clinically important antihypertensive mechanism — the class that includes amlodipine and nifedipine works by exactly that route, preventing calcium entry into vascular smooth muscle so the vessel wall relaxes and peripheral resistance falls. A plant extract showing calcium-antagonist behaviour in an organ bath is showing something mechanistically coherent rather than vague.

Proposed contributing pathways, all from preliminary work:

• Vascular smooth-muscle relaxation via calcium-channel antagonism, lowering peripheral resistance.
• Diuresis — increased sodium and water excretion reduces circulating volume, which is how thiazide diuretics work.
• Improved endothelial function secondary to reduced oxidative stress, potentially increasing nitric oxide availability.
• Central or sedative effects reducing sympathetic tone; the Gilani paper's sedative finding is at least consistent with this.
• Anti-inflammatory activity, since vascular inflammation contributes to arterial stiffness.

All of this is worth knowing and none of it is evidence of an effect in people. Extract applied directly to a tissue strip bypasses digestion, absorption and first-pass liver metabolism entirely. Concentrations are chosen by the experimenter. Anaesthetised rats have blood-pressure physiology that differs from a conscious human's in important ways. Mechanism explains why the question is reasonable; it does not answer it.

Fibrinolysis and the Bleeding Question

Here is the part of the 2009 study that most write-ups omit, and it is the one with a practical consequence.

Alongside the blood-pressure result, the study reported a significant increase in fibrinolytic activity. Fibrinolysis is the body's clot-dissolving system: plasmin breaking down the fibrin mesh that holds a clot together. In the abstract, increasing it sounds unambiguously good — it is broadly the direction cardiovascular medicine wants, and it is why thrombolytic drugs exist.

But it is also, precisely, an effect on haemostasis. Which means:

• If you take warfarin, a direct oral anticoagulant (apixaban, rivaroxaban, dabigatran, edoxaban), clopidogrel or high-dose aspirin, gram-level cardamom is a poor idea. The relevant risk is additive bleeding, and unlike the blood-pressure claim, the downside here is not merely a wasted supplement.
• Stop concentrated cardamom supplements roughly two weeks before planned surgery, dental extraction included, on the same logic used for other supplements with haemostatic effects.
• Tell your doctor if you are taking gram doses and have a bleeding disorder, a history of gastrointestinal bleeding, or a recent stroke.

How strong is this finding? Weak, in isolation — it is one uncontrolled study, and increased fibrinolytic activity on a laboratory assay is not the same as a measured bleeding event. There are no case reports of cardamom-associated bleeding that we can point to. But the asymmetry of consequences is what matters: ignoring an unproven blood-pressure benefit costs you nothing, while ignoring an unproven bleeding interaction can cost a great deal. Culinary cardamom is not the issue here. Chai, coffee and baking are fine. This applies to deliberately taking three grams of powder or capsules daily.

Antioxidant Status and Endothelial Function

Evidence tier: uncontrolled human measurement, plus preliminary mechanism.

The 2009 study reported total antioxidant status rising by around 90 percent over twelve weeks. That number gets quoted heavily and deserves a careful reading.

"Total antioxidant status" is a bulk plasma assay — it measures the capacity of a blood sample to neutralise a reagent in a test tube. It is a legitimate biochemical measurement and a very indirect one. It responds to a wide range of dietary changes, it is sensitive to the specific assay used, and it is not a clinical outcome. Critically, a large body of cardiovascular research has shown repeatedly that improving antioxidant markers does not reliably translate into fewer cardiovascular events — the large randomized trials of vitamin E and beta-carotene supplementation are the cautionary example, having moved antioxidant biomarkers convincingly while failing to reduce cardiovascular endpoints, and in some cases showing harm.

So the plausible chain runs: cardamom's polyphenols and volatile oil reduce oxidative stress → less oxidative inactivation of nitric oxide → better endothelium-dependent vasodilation → lower blood pressure and less arterial stiffness. Each arrow is reasonable. None has been measured in a human being taking cardamom. The 90 percent figure is a change in a proxy of a proxy, in an uncontrolled study, and should be read as encouragement to run a proper trial rather than as a result.

Diuretic and Sedative Effects

Evidence tier: preliminary — rodent work.

Two more findings from the Gilani animal study, both relevant to blood pressure and both frequently overlooked.

The diuretic effect. Increased urine output and sodium excretion lowers circulating volume and therefore blood pressure — the mechanism of the thiazides, still among the best-evidenced first-line antihypertensives. If cardamom has a genuine diuretic action in humans, that would be a plausible contributor. It also raises a caution nobody mentions: a diuretic effect combined with prescription diuretics could in principle affect fluid and electrolyte balance, particularly in older people or anyone with kidney disease. This is theoretical at culinary doses and worth a passing thought at gram doses.

The sedative effect. Cardamom extract showed sedative activity in rodent behavioural testing. Reduced sympathetic nervous activity lowers blood pressure, so this is mechanistically relevant rather than incidental. It is also a reminder that a plant with central nervous system activity in animals is not automatically inert in people — if you take sedatives, sleep medication or anxiolytics, gram doses of an untested plant sedative are not a free action.

What the Meta-Analysis Found About Lipids

Evidence tier: meta-analysis of randomized trials.

Asbaghi, Eslampour, Reiner and colleagues published Effect of green cardamom on lipoproteins, glycemic control and anthropometric parameters: a meta-analysis of randomized clinical trials in Clinical Nutrition ESPEN in 2020, pooling seven randomized trials of green cardamom. This is the highest tier of evidence available for the spice, and its results are narrow.

• Triglycerides fell significantly in the pooled analysis.
• No significant effect on total cholesterol, LDL cholesterol or HDL cholesterol.
• No significant effect on fasting plasma glucose.
• No significant effect on body weight. BMI rose significantly across three small studies — almost certainly noise in a small pool, but it is in the record and worth not hiding.

For cardiovascular purposes, the triglyceride signal is the one real finding, and it should be sized honestly. Raised triglycerides are associated with cardiovascular risk, and lowering them is a legitimate target. But LDL cholesterol is the lipid fraction with the strongest causal evidence for atherosclerotic disease, and cardamom did not move it. A triglyceride change of the magnitude a spice produces is also small relative to what diet composition, alcohol intake, body weight and glycaemic control do to triglycerides — those are the levers that matter.

Salt, Potassium and the Much Bigger Lever

There is an argument for cardamom in hypertension that is stronger than any of its pharmacology, and it has nothing to do with cardamom's chemistry.

Sodium reduction has robust randomized evidence for lowering blood pressure. It is one of the best-established non-drug interventions there is. And the practical obstacle to reducing salt is almost never knowledge — it is that low-salt food tastes flat, so people abandon the change within weeks.

Aromatic spices solve that problem. Cardamom, cinnamon, cumin, coriander, black pepper, clove and ginger deliver intensity, complexity and warmth with no sodium at all. A rice dish perfumed with cardamom and clove does not need as much salt to be interesting. If cardamom helps you eat less salt, it is lowering your blood pressure — not through calcium-channel blockade, but by making a proven intervention sustainable. That mechanism is boring, unglamorous, and better evidenced than anything else on this page.

Worth pairing with the rest of what actually works for blood pressure: weight reduction where relevant, regular aerobic activity, limiting alcohol, adequate sleep, treating sleep apnoea, and increasing dietary potassium from vegetables, fruit and legumes. A dietary pattern along those lines has randomized trial evidence behind it. A spice does not compete with that list; it can help you stick to it.

Using Cardamom Alongside Blood-Pressure Medication

Practical guidance, given everything above.

• Do not reduce or stop any antihypertensive medication on the strength of cardamom. Nothing on this page comes close to justifying that, and uncontrolled hypertension causes strokes, heart failure and kidney damage silently over years.
• Culinary cardamom needs no special handling. Chai, coffee, curry, cake — use it freely. All the cautions below concern deliberate gram-level dosing.
• If you take an anticoagulant or antiplatelet drug, stay at culinary amounts. This is the firmest caution on the page. See the fibrinolysis section.
• If you take an antihypertensive and want to try 3 g/day anyway, tell your doctor, and monitor at home with a validated upper-arm cuff. Measure at the same time of day, seated, after five minutes of rest, and record the numbers rather than remembering them. If readings drift low or you feel light-headed on standing, stop and report it.
• If you take a prescription diuretic, be aware of the animal diuretic finding, especially if you are older or have reduced kidney function.
• Stop concentrated supplements two weeks before surgery.
• Pregnancy: culinary use is safe and universal; gram-level doses have not been studied. Hypertension in pregnancy is a serious condition requiring obstetric management, never self-treatment.
• Known gallstones: keep to food amounts, per cardamom's traditional cholagogue caution.

The Defensible Bottom Line

Stated as precisely as the evidence allows:

Green cardamom at 3 grams per day was associated with a fall in blood pressure over twelve weeks in a single uncontrolled study of twenty adults with newly diagnosed stage 1 hypertension. That study had no control group and no blinding, and its result is fully explicable by regression to the mean, habituation to measurement and behaviour change during a trial. No controlled trial has tested cardamom for blood pressure. Animal and isolated-tissue work provides a coherent calcium-antagonist and diuretic mechanism. A meta-analysis of seven randomized trials found lower triglycerides and no effect on cholesterol fractions. The same uncontrolled study reported increased fibrinolytic activity, which is a reason for caution with anticoagulants.

That is a much smaller claim than the internet's version, and it is the one the data supports. Cardamom at culinary doses is a pleasant, safe, sodium-free flavouring that may help you eat less salt, which is worth more than any of its putative pharmacology.

Key Research Papers

Each citation is given as a PubMed search with the paper's title, journal and year in the text, so you can confirm the record. Search links cannot resolve to the wrong paper.

1. Verma SK, Jain V, Katewa SS. Blood pressure lowering, fibrinolysis enhancing and antioxidant activities of cardamom (Elettaria cardamomum). Indian Journal of Biochemistry and Biophysics, 2009. Twenty adults, newly diagnosed stage 1 hypertension, 3 g/day, twelve weeks, no control group. Find on PubMed — uncontrolled human pilot study.
2. Gilani AH, Jabeen Q, Khan AU, Shah AJ. Gut modulatory, blood pressure lowering, diuretic and sedative activities of cardamom. Journal of Ethnopharmacology, 2008. The calcium-antagonist, diuretic and sedative findings. Find on PubMed — preliminary.
3. Asbaghi O, Eslampour E, Reiner Ž, et al. Effect of green cardamom on lipoproteins, glycemic control and anthropometric parameters: a meta-analysis of randomized clinical trials. Clinical Nutrition ESPEN, 2020. Seven pooled trials; triglycerides down, cholesterol fractions unchanged. Find on PubMed — meta-analysis of randomized trials.
4. Ashokkumar K, Murugan M, Dhanya MK, Warkentin TD. Botany, traditional uses, phytochemistry and biological activities of cardamom [Elettaria cardamomum (L.) Maton] — a critical review. Journal of Ethnopharmacology, 2020. Find on PubMed — review.
5. Cardamom and blood pressure, randomized controlled trials — run it; the shortage of results is the central point of this page.
6. Regression to the mean in blood-pressure studies — the statistical artefact that explains most single-arm hypertension results.
7. White-coat effect and habituation on repeated blood-pressure measurement — the second artefact stacked on the first.
8. Sodium reduction and blood pressure, randomized meta-analyses — the intervention spices can genuinely support.
9. Dietary pattern trials in hypertension — the evidence-based context any spice sits inside.
10. Antioxidant supplementation and cardiovascular outcomes — why an improved antioxidant marker is not a clinical result.
11. Fibrinolysis, plasminogen activation and bleeding risk — the physiology behind the anticoagulant caution.
12. Herbal supplement interactions with warfarin — the general pattern this caution belongs to.
13. Triglycerides, LDL cholesterol and cardiovascular causality — why the one positive lipid finding is modest.

Safety and Disclaimer

Cardamom is safe in culinary quantities and was well tolerated at 3 grams a day for twelve weeks in the study described above. It is not a treatment for high blood pressure, and nothing on this page justifies reducing or stopping an antihypertensive medication. Uncontrolled hypertension damages the brain, heart, kidneys and eyes silently over years; it is one of the conditions where self-treatment does the most harm. If you take warfarin, a direct oral anticoagulant, clopidogrel or high-dose aspirin, keep cardamom to food amounts because of the reported increase in fibrinolytic activity, and stop concentrated supplements about two weeks before surgery. Keep to culinary amounts also if you have known gallstones or are pregnant. If you choose to take gram doses alongside prescription medication, tell your doctor and monitor your own blood pressure with a validated cuff. This page is educational and is not medical advice.

Connections

• All Herbs
• Cardamom (Elettaria cardamomum) — the main topic page: botany, green versus black, dosage, cautions.
• Cardamom — Benefits Deep Dive — the hub for all four benefit articles.
• Cardamom's Metabolic and Antioxidant Effects — where the placebo-controlled trials actually are.
• Hypertension — what genuinely lowers blood pressure, and why it matters.
• Cardiovascular Disease — the outcome all of this is a proxy for.
• Atherosclerosis — the process LDL cholesterol drives, and cardamom does not touch.
• Cholesterol Management — context for the lipid findings above.
• Lipid Panel — where a triglyceride change would appear.
• hs-CRP — the inflammatory marker cardamom trials have moved.
• Potassium — the dietary mineral with real blood-pressure evidence.
• Magnesium — another mineral with a modest but genuine blood-pressure literature.
• Hibiscus — the herb with the most credible randomized blood-pressure evidence.
• Hawthorn — the traditional cardiac herb, with its own trial record.
• Garlic — the kitchen plant with the largest blood-pressure trial base.
• Cinnamon — Benefits — the other warm spice with metabolic claims and replication problems.

Back to Table of Contents